Drug Profile
Research programme: irritable bowel syndrome therapeutics - Asterand
Alternative Names: PGN1091; PGN1164; R1 programme - AsterandLatest Information Update: 13 Feb 2007
Price :
$50
*
At a glance
- Originator Asterand plc
- Class
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 13 Feb 2007 Discontinued - Preclinical for Irritable bowel syndrome in United Kingdom (PO)
- 30 Jan 2006 Pharmagene has merged with Asterand to form Asterand plc
- 29 Apr 2005 Development of PGN 1164 has been discontinued